TriNetX Acquires Zetta Genomics, Forging New Path in Precision Medicine

CAMBRIDGE, Mass. and CAMBRIDGE, United Kingdom – April 07, 2026 – TriNetX, a global leader in federated health data, announced today its acquisition of key assets from UK-based Zetta Genomics. The move, which includes the powerful XetaBase® multiomic data platform, signals a major push to integrate vast genomic and clinical datasets, potentially accelerating a new era of precision medicine and clinical research.

The acquisition builds on a successful two-year partnership and solidifies TriNetX's position at the forefront of a paradigm shift in biomedical research, moving beyond siloed information toward a holistic, multi-layered understanding of human health.

A Strategic Leap into Multiomics

The integration of Zetta Genomics' technology represents a significant enhancement of TriNetX's capabilities, specifically in the rapidly advancing field of multiomics. This discipline involves analyzing multiple layers of biological data—such as genomics, proteomics, and metabolomics—alongside traditional clinical (phenotypic) data from electronic health records. The combination provides a far richer and more detailed picture of disease mechanisms and patient responses.

At the heart of the acquisition is XetaBase, Zetta's flagship platform. Born from insights gained during Genomics England's landmark 100,000 Genomes Project, XetaBase is engineered for population-scale genomic analysis. It can index and query hundreds of thousands of whole genomes and billions of genetic variants in seconds, a task that would be slow and prohibitively expensive with legacy systems. Its design allows for the secure, federated capture of this complex data, meaning sensitive information remains within the control of the local healthcare institution.

"Welcoming Zetta's XetaBase platform into the TriNetX ecosystem represents an important milestone for our organization," said Jeff Margolis, Executive Chairman of TriNetX, in a statement. "This acquisition reflects our commitment to advancing multiomic-enabled research and supporting healthcare providers with a practical, localized approach to scaling their data infrastructures."

This commitment is echoed by the company's scientific leadership, who see the integration of diverse data types as fundamental to progress. "Our purpose of driving better human health through data is clearly enhanced by adding the XetaBase technology," added Jeffrey Brown, PhD, TriNetX Chief Scientific Officer. "We strongly believe the integration of different data types is essential to clinical and scientific progress."

Redefining the Health Data Landscape

This acquisition is more than a simple technology transfer; it is a strategic maneuver that reshapes the competitive landscape for health data and real-world evidence. The health tech market is rapidly evolving, with a clear trend of vendors moving beyond standard electronic health record aggregation. The new frontier is infrastructure that can handle federated, multiomic analysis while adhering to stringent privacy and data locality controls.

By bringing XetaBase in-house, TriNetX strengthens its value proposition against a host of competitors. It enhances its standing in the real-world evidence market, where companies like IQVIA and Truveta also vie for dominance, by adding a sophisticated layer of genomic capability that is increasingly in demand. Furthermore, it positions TriNetX to compete more directly with specialized bioinformatics and multiomic platform providers.

The move is widely seen by industry analysts as a consolidation of power in a high-growth sector. The genomics market has experienced explosive growth, fueled by decreasing sequencing costs and a global push toward personalized healthcare. Platforms like XetaBase are considered crucial enabling technologies that allow researchers and clinicians to make sense of the resulting data deluge. This acquisition allows TriNetX to not only provide access to data but also to offer the advanced tools required to interpret it at scale.

From Research Bench to Patient Bedside

The ultimate goal of integrating such complex data is to translate scientific insights into tangible patient benefits. By connecting the dots between a patient's genetic makeup and their clinical journey, healthcare providers can unlock new possibilities for diagnostics, treatment, and preventative care.

For life science companies and academic researchers using the TriNetX network, the integration of XetaBase promises to streamline and accelerate drug discovery and development. Researchers can now more easily identify genetic markers for disease, discover novel drug targets, and design more precise and effective clinical trials by stratifying patient populations based on their molecular profiles. This ability to conduct large-scale, multiomic research in a cost-effective manner is expected to shorten development timelines and increase the success rate of new therapies.

For healthcare providers, the enhanced platform offers the potential to deliver truly personalized medicine. Clinicians could leverage integrated genomic and phenotypic data to make more accurate diagnoses, predict a patient's risk for certain conditions, and select the most effective treatment with the fewest side effects.

TriNetX has assured that the transition will be seamless for existing Zetta Genomics customers, stating it will continue to support all users of the XetaBase technology. These organizations, which include leading healthcare providers and research institutes, now stand to benefit from access to TriNetX's vast global network, which spans over 11,000 sites in more than 20 countries.

The Federated Future of Genomic Data

Central to the success of this integration is the federated model that both companies champion. In a federated network, data remains physically located at the source institution, such as a hospital or research center. TriNetX's platform sends queries to the data, and only aggregated, de-identified results are returned to the researcher. This approach is critical for handling highly sensitive genomic information, as it ensures privacy, security, and institutional control.

This model builds the trust necessary for healthcare organizations to participate in large-scale data networks. By acquiring a platform built on these same principles, TriNetX reinforces its core mission.

"From the beginning, our collaboration with TriNetX demonstrated that genomic and clinical data can be securely connected in a federated way at scale," noted Ignacio Medina Castello, CEO and CTO of Zetta Genomics. "Fully joining forces with TriNetX allows that work to move forward faster and to reach a broader global community of healthcare and research partners."

As the volume of health data continues to grow exponentially, this federated approach to connecting and analyzing genomic and clinical information represents a sustainable and scalable path forward, paving the way for the next wave of data-driven breakthroughs in human health.